← Browse by Condition
Medical Condition
refractory chronic myelogenous leukemia bcr abl1 positive
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 2
NCT05857969 Phase 1
Recruiting
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Enrollment
65 pts
Location
United States
Sponsor
Florida International Universi...
NCT02115295 Phase 2
Recruiting
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Enrollment
508 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center